Dmitry Zaitsev, JSC Pharmstandard CEO, takes part in the “Ensuring Drug Security” Forum. On the day “zero” of SPIEF-2024, the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (APMEAEU) hosted a panel on implementing the Pharma-2030 Pharmaceutical Industry Development Strategy.

The panel was attended by Ekaterina Priezzheva, Deputy Minister of Industry and Trade of the Russian Federation; Timofei Nizhegorodtsev, Deputy Head of the Federal Antimonopoly Service; Elena Astapenko, Director of the Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices of the Ministry of Health of the Russian Federation; Evgeny Nifantiev, Deputy Chairman of the State Duma Health Protection Committee; Stanislav Naumov, Deputy Chairman of the State Duma Committee on Economic Policy; Irina Filatova, State Duma deputy, member of the State Duma Committee on Competition Protection; Victoria Galkovskaya, Deputy Head of the Federal Service for Intellectual Property (Rospatent); and heads of major domestic pharmaceutical companies.

The Pharma-2030 Pharmaceutical Industry Development Strategy is one year old, and according to the DSM Group, the size of the Russian pharmaceutical market increased to 2578 billion roubles in 2023. The Government-approved Strategy Implementation Plan includes a wide range of measures to support the pharmaceutical industry with thorough planning for the next 3 years. However, new national projects such as “Long and Active Life”, “Modern Health-Saving Technologies”, “New Materials and Chemistry”, “Human Resources”, and “Export” extend the planning horizon to 2030 and for the period up to 2036.

Alexey Kedrin, the panel moderator and Chairman of the Board of the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (APMEAEU), noted that healthcare issues require long-term planning. “As daily work on drug security continues, the patient community, the scientific community, including R&D centres, as well as regulators, pharmaceutical and chemical companies now jointly elaborate additional regulatory and support measures required to ensure drug security up to 2030 and 2036 progressively,” the APMEAEU head stressed.

While reviewing the first year results of the Pharma-2030 Strategy adoption, the panel participants noted the relevance of developing the proposals to modernise the Strategy, namely the following aspects: improving the regulation system for medicines supply, upgrading the domestic pharmaceutical industry support tools, including those in the field of innovative developments, manufacturing of active pharmaceutical ingredients and components to produce them.

Dmitry Zaitsev, JSC Pharmstandard CEO, considers it strategically important to further develop constructive dialogue between the regulator and market participants: “For the last two decades, we have seen an active growth of domestic pharmaceutical production. This was largely due to the previous Pharma-2020 industry development strategy and timely regulatory measures. Partly owing to thoughtful and implemented initiatives we managed to navigate the turbulence and gracefully confront the challenges of the COVID‑19 pandemic. Today, the pharmaceutical industry faces new, no less global, tasks. Eurasian economic integration is in its active phase, supply chains and logistics are being restructured, the external factors get more and more influence on the economy. Given this situation, it’s crucial for us to cooperate in finding optimal and practical solutions. We expect for a further balanced approach to developing influence and support measures based on a constructive dialogue with market participants and on in-depth forecast analytics considering the complex impact of regulatory measures implemented”.

To learn more, visit the website of the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (APMEAEU)

Link to the recorded session “The Day of Today – Looking into the Future. PHARMA-2030 and the long-term planning course”